Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: HonorHealth Research Institute Clear all

Conditions: Migraine
Interventions: Eucalyptus Oil Scent, Isopropyl Alcohol Vapors; Other
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Alopecia
Interventions: Paxman Scalp Cooling Device; Device
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Interventions: Ascorbic Acid, Paclitaxel protein-bound, Cisplatin, Gemcitabine; Drug
Lead sponsor: Hitendra Patel; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
Interventions: Paclitaxel Protein Bound (Abraxane); Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Hematopoietic Stem Cell Transplantation, Bone Marrow Transplant, Heart Rate Variability, Autonomic Nervous System, Stress, Mood, Psychological Distress, Emotion Regulation, Communication Research, Narrative
Interventions: Baseline Surveys, Heart rate variability biofeedback, Heart rate variability waitlist and Digital storytelling Control intervention; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: SCCOHT, Ovarian Clear Cell Tumor, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer
Interventions: SP-2577, Pembrolizumab; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreas Metastases
Interventions: High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2, Gemcitabine 1000mg/m^2, High Dose Ascorbic Acid 37.5 g/m^2, High Dose Ascorbic Acid 56.25 g/m^2, High Dose Ascorbic Acid 75 g/m^2; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases, Adenocarcinoma
Interventions: Paricalcitol (Zemplar); Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Traumatic Brain Injury
Interventions: N-Acetyl cysteine; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 60 Years to 100 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions: Dual Antiplatelet (DAPT) Therapy, The Synergy® stent; Drug · Device
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 75 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • New York, New York

Conditions: Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions: Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Pancreas Cancer
Interventions: Vemurafenib, Sorafenib; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: NabCG (nab-Paclitaxel + Cisplatin + Gemcitabine); Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 105 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Scottsdale, Arizona • Miami, Florida • New Orleans, Louisiana + 1 more

Conditions: Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Interventions: Ascorbic Acid, Paclitaxel protein-bound, Cisplatin, Gemcitabine; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Scottsdale, Arizona • San Diego, California • Atlanta, Georgia + 3 more

Conditions: Covid19
Interventions: Atovaquone/Azithromycin; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 95 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Gastrointestinal Malignancies
Interventions: Lurbinectedin 4 MG Injection [Zepzelca]; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Interventions: Paclitaxel protein bound, Gemcitabine, Cisplatin, Hydroxychloroquine; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Metastatic Pancreatic Cancer
Interventions: Safety Laboratories, AE Assessment, Physical Exam, Concomitant Medication Review, Tumor Imaging, nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate, FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate, Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate; Diagnostic Test · Other · Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 105 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Hysterectomy
Interventions: Not listed
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: Female only
Enrollment: 50 participants
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
Interventions: Tegavivint; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Multi-gene Next Generation Sequencing Panel; Genetic
Lead sponsor: Ambry Genetics; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Nivolumab, Albumin-bound paclitaxel, Paricalcitol, Cisplatin, Gemcitabine; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Adenocarcinoma of Pancreas
Interventions: Hand Therapy Until CIPN, Traditional Occupational Therapy (TOT); Other
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Pancreas Cancer
Interventions: Pemigatinib 4.5 MG; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Search by objective public record fields.

Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine

Hair Loss Prevention Study for Pancreatic Cancer

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients

Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

The Seven Trial: Exploiting the Unfolded Protein Response

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

A Standardized Bundle Protocol to Optimize Outcomes With Patients Undergoing Gynecological Surgery

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas